Atypical patterns of response to immune checkpoint inhibitors: interpreting pseudoprogression and hyperprogression in decision making for patients' treatment.
作者信息
Onesti Concetta Elisa, Frères Pierre, Jerusalem Guy
机构信息
Laboratory of Human Genetics, GIGA Research Institute, University of Liège, Liège, Belgium.
Department of Medical Oncology, University Hospital (CHU Liège), Liège, Belgium.
出版信息
J Thorac Dis. 2019 Jan;11(1):35-38. doi: 10.21037/jtd.2018.12.47.
Abstract
摘要
相似文献
1
Atypical patterns of response to immune checkpoint inhibitors: interpreting pseudoprogression and hyperprogression in decision making for patients' treatment.免疫检查点抑制剂的非典型反应模式：在患者治疗决策中解读假性进展和超进展
J Thorac Dis. 2019 Jan;11(1):35-38. doi: 10.21037/jtd.2018.12.47.
2
Pseudoprogression and hyperprogression in lung cancer: a comprehensive review of literature.肺癌中的假性进展和超进展：文献综述
J Cancer Res Clin Oncol. 2020 Dec;146(12):3269-3279. doi: 10.1007/s00432-020-03360-1. Epub 2020 Aug 28.
3
Pseudoprogression and hyperprogression after checkpoint blockade.免疫检查点抑制剂治疗后的假性进展和超进展。
Int Immunopharmacol. 2018 May;58:125-135. doi: 10.1016/j.intimp.2018.03.018. Epub 2018 Mar 23.
4
Biomarkers of hyperprogression and pseudoprogression with immune checkpoint inhibitor therapy.免疫检查点抑制剂治疗的超进展和假性进展的生物标志物。
Future Oncol. 2019 Aug;15(22):2645-2656. doi: 10.2217/fon-2019-0183. Epub 2019 Jul 12.
5
Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer.免疫检查点抑制剂治疗尿路上皮癌和肾癌中的假性进展和超进展。
World J Urol. 2018 Nov;36(11):1703-1709. doi: 10.1007/s00345-018-2264-0. Epub 2018 Mar 16.
6
Hyperprogression under Immunotherapy.免疫治疗下的超进展。
Int J Mol Sci. 2019 May 30;20(11):2674. doi: 10.3390/ijms20112674.
7
[Monitoring of immunotherapy : Possibilities and limitations].[免疫疗法的监测：可能性与局限性]
Radiologe. 2020 Aug;60(8):711-720. doi: 10.1007/s00117-020-00726-x.
8
Pitfalls in the radiological response assessment of immunotherapy.免疫疗法放射学反应评估中的陷阱。
Memo. 2018;11(2):138-143. doi: 10.1007/s12254-018-0389-x. Epub 2018 Mar 21.
9
Hyperprogression after immunotherapy: A comprehensive review.免疫治疗后的超进展：全面综述。
J BUON. 2019 Nov-Dec;24(6):2232-2241.
10
Critical features and challenges associated with imaging in patients undergoing cancer immunotherapy.癌症免疫治疗患者影像学检查的关键特征和挑战。
Crit Rev Oncol Hematol. 2017 Dec;120:13-21. doi: 10.1016/j.critrevonc.2017.09.017. Epub 2017 Oct 10.
引用本文的文献
1
Molecular MRI of T-cell immune response to cryoablation in immunologically hot . cold hepatocellular carcinoma.免疫活性高/低的肝细胞癌中T细胞对冷冻消融免疫反应的分子磁共振成像
JHEP Rep. 2024 Dec 4;7(3):101294. doi: 10.1016/j.jhepr.2024.101294. eCollection 2025 Mar.
2
Design Principles of an Engineered Metastatic Niche for Monitoring of Cancer Progression.用于监测癌症进展的工程化转移微环境的设计原则
Biotechnol Bioeng. 2025 Mar;122(3):631-641. doi: 10.1002/bit.28895. Epub 2024 Dec 3.
3
Total metabolic tumor volume on F-FDG PET/CT is a game-changer for patients with metastatic lung cancer treated with immunotherapy.氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描的总代谢肿瘤体积是免疫治疗转移性肺癌患者的改变游戏规则的因素。
J Immunother Cancer. 2024 Apr 22;12(4):e007628. doi: 10.1136/jitc-2023-007628.
4
Anti-PD-1 Therapy in Advanced Pediatric Malignancies in Nationwide Study: Good Outcome in Skin Melanoma and Hodgkin Lymphoma.全国性研究中晚期儿童恶性肿瘤的抗PD-1治疗：皮肤黑色素瘤和霍奇金淋巴瘤疗效良好
Cancers (Basel). 2024 Feb 28;16(5):968. doi: 10.3390/cancers16050968.
5
FDG-PET/CT in the Monitoring of Lymphoma Immunotherapy Response: Current Status and Future Prospects.18F-氟代脱氧葡萄糖正电子发射断层显像/计算机断层扫描在淋巴瘤免疫治疗反应监测中的应用：现状与未来展望
Cancers (Basel). 2023 Feb 7;15(4):1063. doi: 10.3390/cancers15041063.
6
Concurrent immunotherapy and re-irradiation utilizing stereotactic body radiotherapy for recurrent high-grade gliomas.同期免疫治疗和立体定向体部放射治疗复发性高级别胶质瘤。
Cancer Rep (Hoboken). 2023 Jul;6(7):e1788. doi: 10.1002/cnr2.1788. Epub 2023 Feb 7.
7
A Complete Sustained Response of Advanced Non-Small-Cell Lung Cancer After Immune Checkpoint Inhibitor, Radiotherapy, and Chemotherapy.免疫检查点抑制剂、放疗和化疗后晚期非小细胞肺癌的完全持续缓解
Cureus. 2022 Dec 16;14(12):e32585. doi: 10.7759/cureus.32585. eCollection 2022 Dec.
8
The efficacy of PD-1 inhibitors in patients with salivary gland carcinoma: A retrospective observational study.PD-1抑制剂在涎腺癌患者中的疗效：一项回顾性观察研究。
Laryngoscope Investig Otolaryngol. 2022 Nov 3;7(6):1808-1813. doi: 10.1002/lio2.863. eCollection 2022 Dec.
9
Comparison of the efficacy and safety in the treatment strategies between chemotherapy combined with antiangiogenic and with immune checkpoint inhibitors in advanced non-small cell lung cancer patients with negative PD-L1 expression: A network meta-analysis.PD-L1表达阴性的晚期非小细胞肺癌患者中化疗联合抗血管生成与化疗联合免疫检查点抑制剂治疗策略的疗效和安全性比较：一项网状Meta分析
Front Oncol. 2022 Nov 29;12:1001503. doi: 10.3389/fonc.2022.1001503. eCollection 2022.
10
Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy.系统性 CD4 免疫与 PD-L1/PD-1 阻断免疫疗法。
Int J Mol Sci. 2022 Oct 31;23(21):13241. doi: 10.3390/ijms232113241.
本文引用的文献
1
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.阿替利珠单抗联合白蛋白紫杉醇治疗晚期三阴性乳腺癌。
N Engl J Med. 2018 Nov 29;379(22):2108-2121. doi: 10.1056/NEJMoa1809615. Epub 2018 Oct 20.
2
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.度伐利尤单抗化疗和放疗后用于 III 期非小细胞肺癌的总生存。
N Engl J Med. 2018 Dec 13;379(24):2342-2350. doi: 10.1056/NEJMoa1809697. Epub 2018 Sep 25.
3
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.阿替利珠单抗联合化疗一线治疗广泛期小细胞肺癌。
N Engl J Med. 2018 Dec 6;379(23):2220-2229. doi: 10.1056/NEJMoa1809064. Epub 2018 Sep 25.
4
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.帕博利珠单抗联合化疗用于鳞状非小细胞肺癌。
N Engl J Med. 2018 Nov 22;379(21):2040-2051. doi: 10.1056/NEJMoa1810865. Epub 2018 Sep 25.
5
Patterns of Response and Progression to Immunotherapy.免疫疗法的反应和进展模式。
Am Soc Clin Oncol Educ Book. 2018 May 23;38:169-178. doi: 10.1200/EDBK_200643.
6
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.抗 PD-1/PD-L1 抑制剂或单药化疗治疗的晚期非小细胞肺癌患者的超进展性疾病。
JAMA Oncol. 2018 Nov 1;4(11):1543-1552. doi: 10.1001/jamaoncol.2018.3676.
7
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.帕博利珠单抗联合化疗治疗转移性非小细胞肺癌。
N Engl J Med. 2018 May 31;378(22):2078-2092. doi: 10.1056/NEJMoa1801005. Epub 2018 Apr 16.
8
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.纳武利尤单抗联合伊匹单抗治疗高肿瘤突变负荷肺癌。
N Engl J Med. 2018 May 31;378(22):2093-2104. doi: 10.1056/NEJMoa1801946. Epub 2018 Apr 16.
9
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.帕博利珠单抗辅助治疗与安慰剂对照用于 III 期黑色素瘤完全切除术后患者的随机、双盲、III 期临床试验
N Engl J Med. 2018 May 10;378(19):1789-1801. doi: 10.1056/NEJMoa1802357. Epub 2018 Apr 15.
10
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.纳武利尤单抗联合伊匹木单抗与舒尼替尼治疗晚期肾细胞癌的比较
N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21.
Zotero 插件